Followers | 4053 |
Posts | 151256 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Monday, December 30, 2013 4:14:46 PM
Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test - AmpliVue(R) Group B Strep Assay
Alert
Quidel (NASDAQ:QDEL)
Intraday Stock Chart
Today : Monday 30 December 2013
Click Here for more Quidel Charts. Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test - AmpliVue(R) Group B Strep Assay
SAN DIEGO, CA--(Marketwired - Dec 30, 2013) - Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its AmpliVue Group B Strep Assay. AmpliVue is Quidel's non-instrumented molecular diagnostic test that employs a novel amplification technology with an easy-to-use, hand-held device. The AmpliVue Group B Strep Assay combines isothermal Helicase Dependent Amplification (HDA) with Quidel's well-established expertise in lateral flow technology to detect Group B Streptococcus (GBS) from enriched broth cultures of specimens from antepartum women.
GBS is responsible for illness in people of all ages, but it is a particularly serious pathogen for newborns in whom it can cause life-threatening sepsis, pneumonia and sometimes meningitis with a risk for long lasting effects, including deafness and developmental disabilities.1 According to the Centers for Disease Control and Prevention (CDC), roughly 10% to 30% of pregnant women carry GBS that can be transmitted to the newborn at delivery. CDC guidelines recommend that all pregnant women should be tested for GBS infection between 35 and 37 weeks of pregnancy.2
Although more rare, serious GBS infections can also occur in adults, leading to bloodstream infections, pneumonia, and other infections that can be fatal.3
"We are pleased to receive 510(k) clearance for our AmpliVue Group B Strep assay," said Douglas Bryant, president and chief executive officer of Quidel Corporation. "We can now provide the hospital laboratories with another AmpliVue assay for fast, accurate infectious disease testing without the need for additional investments in expensive equipment."
The AmpliVue Group B Strep assay now enables laboratories of all sizes to perform highly sensitive and specific molecular tests and is Quidel's second assay to launch in the hand-held, disposable AmpliVue format. The AmpliVue C. difficile assay was launched earlier this year for the detection of toxigenic Clostridium difficile bacterial DNA. Both assays are now available for sale throughout the U.S. and Europe. Diagnostic tests for other analytes of interest that will use the novel AmpliVue platform are in development.
1 http://www.cdc.gov/groupbstrep/about/index.html
2 http://www.cdc.gov/groupbstrep/about/fast-facts.html
3 http://www.cdc.gov/groupbstrep/about/adults.html
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue®, D3® Direct Detection and Thyretain® leading brand names, as well as under the new Sofia® and AmpliVue® brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
Recent QDEL News
- Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 05/03/2024 09:45:00 AM
- QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer • Business Wire • 05/02/2024 12:00:00 PM
- QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - QDEL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) - June 11, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/19/2024 10:40:00 AM
- QuidelOrtho To Report First Quarter 2024 Financial Results • Business Wire • 04/17/2024 11:00:00 AM
- QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay • Business Wire • 04/10/2024 11:00:00 AM
- QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test • Business Wire • 04/02/2024 01:00:00 PM
- QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada • Business Wire • 03/06/2024 09:35:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/29/2024 09:40:55 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 08:29:59 PM
- QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference • Business Wire • 02/26/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 12:30:20 PM
- QuidelOrtho Announces Changes in Executive Leadership • Business Wire • 02/21/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 09:08:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 09:07:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 12:00:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:07:22 PM
- QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results • Business Wire • 02/13/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 02:44:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 02:43:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 01:08:22 AM
- QuidelOrtho to Report Fourth Quarter and Full-year 2023 Financial Results • Business Wire • 01/23/2024 12:00:00 PM
- QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 12/22/2023 12:00:00 PM
- QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay • Business Wire • 12/20/2023 09:05:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:14:22 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM